



ORIGINAL RESEARCH

Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed T_H1/T_H2 Response Independent of Differentiation



Iva Xhangolli^{1,2,a}, Burak Dura^{1,2,b}, GeeHee Lee^{1,2,c}, Dongjoo Kim^{1,2,d},
 Yang Xiao^{1,2,e}, Rong Fan^{1,2,3,*f}

¹ Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA

² Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA

³ Yale Stem Cell Center, Yale School of Medicine, New Haven, CT 06520, USA

Received 10 March 2019; accepted 19 March 2019

Available online 20 June 2019

Handled by Yun-Gui Yang

KEYWORDS

Single-cell transcriptomics;
 Single-cell proteomics;
 CAR-T;
 T cell activation

Abstract The activation mechanism of chimeric antigen receptor (CAR)-engineered T cells may differ substantially from T cells carrying native T cell receptor, but this difference remains poorly understood. We present the first comprehensive portrait of single-cell level transcriptional and cytokine signatures of anti-CD19/4-1BB/CD28/CD3ζ CAR-T cells upon antigen-specific stimulation. Both CD4⁺ helper T (T_H) cells and CD8⁺ cytotoxic CAR-T cells are equally effective in directly killing target tumor cells and their cytotoxic activity is associated with the elevation of a range of T_H1 and T_H2 signature cytokines, *e.g.*, interferon γ , tumor necrotic factor α , interleukin 5 (IL5), and IL13, as confirmed by the expression of master transcription factor genes *TBX21* and *GATA3*. However, rather than conforming to stringent T_H1 or T_H2 subtypes, single-cell analysis reveals that the predominant response is a highly mixed T_H1/T_H2 function in the same cell. The regulatory T cell activity, although observed in a small fraction of activated cells, emerges from this hybrid T_H1/T_H2 population. Granulocyte-macrophage colony stimulating factor (GM-CSF) is produced from the majority of cells regardless of the polarization states, further contrasting CAR-T to classic T cells. Surprisingly, the cytokine response is minimally associated with differentiation

* Corresponding author.

E-mail: rong.fan@yale.edu (Fan R).

^a ORCID: 0000-0002-2170-2867.

^b ORCID: 0000-0002-3875-1649.

^c ORCID: 0000-0002-1513-4314.

^d ORCID: 0000-0002-2909-8166.

^e ORCID: 0000-0001-7878-4923.

^f ORCID: 0000-0001-7805-8059.

Peer review under responsibility of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.

<https://doi.org/10.1016/j.gpb.2019.03.002>

1672-0229 © 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

status, although all major differentiation subsets such as naïve, central memory, effector memory, and effector are detected. All these suggest that the activation of CAR-engineered T cells is a canonical process that leads to a highly mixed response combining both type 1 and type 2 cytokines together with GM-CSF, supporting the notion that polyfunctional CAR-T cells correlate with objective response of patients in clinical trials. This work provides new insights into the mechanism of CAR activation and implies the necessity for cellular function assays to characterize the quality of CAR-T infusion products and monitor therapeutic responses in patients.

Introduction

Adoptive transfer of anti-CD19 chimeric antigen receptor (CAR) T cells has demonstrated remarkable efficacy in treating patients with B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and other indolent lymphomas [1–4]. Despite the demonstrated success, there exist large variation of responses and unpredictable toxicity in patients [5,6], which could be attributed in part to inter-patient and intra-population heterogeneity of CAR-T infusion product. This makes it imperative to develop a high-resolution approach to characterize not only phenotypic composition but also the function of CAR-T cells at the systems level. The single-chain variable fragment (scFv) ectodomain of CAR binds to CD19 expressed on the surface of a target tumor cell and transmits signal via the transmembrane linker to the intracellular signaling domain such as CD3 ζ to elicit T cell activation. This process is independent of the signaling from T cell receptor (TCR)-mediated binding to the peptide major histocompatibility complex (p-MHC) [7]. Incorporating a co-stimulator domain such as CD28 or 4-1BB (CD137) in the second generation CAR further enhanced proliferation, persistence, and potency [8]. Therefore, the mechanism of CAR-T activation could differ substantially from that of classic T cells. Nonetheless, this speculation remains inadequately tested as of today. The questions like how different CAR-T cell subsets, such as CD4⁺ helper T cells and CD8⁺ cytotoxic cells, respond to CAR stimulation, how the polarization subtypes, such as T_H1, T_H2, and regulatory T (T_{reg}) cells, differentially control CAR-T cell responses, and how the differentiation status could affect the activation state, are all yet to be fully elucidated.

Current methods for evaluating CAR-T cell activation include the measurement of interferon (IFN)- γ secretion by ELISA or the detection of IFN γ -secreting cells by ELISpot [9,10]. Multiparameter flow cytometry was used for immunophenotyping of CAR-T cells, which is one of the mainstay techniques used for monitoring CAR-T product manufacturing, but the number of markers and functions (cytokines) it can measure is limited [11,12]. Intra-cellular cytokine staining for flow cytometric analysis is not a true secretion assay and often leads to over-estimation of cytokine-secreting cells. Recently, Xue et al used single-cell multiplex cytokine profiling to measure the cytokine output of anti-CD19/4-1BB/CD3 ζ CAR-T cells using CD19-coated beads and revealed a diverse polyfunctional response upon activation [13]. However, the cytokine profile of a CAR-T cell is yet to be directly correlated to cytotoxicity, subtype, and signaling in order to elucidate the underlying mechanisms.

Herein, we use high-throughput single-cell 3' mRNA transcriptome sequencing [14,15], single-cell multiplex cytokine

secretion assay [13,16,17], together with live cell imaging of cytotoxic activity to interrogate third-generation anti-CD19/4-1BB/CD28/CD3 ζ (CD19-BB-28-3z) CAR-T cells, yielding the first comprehensive portrait of single-cell level transcriptional [18] and cytokine signatures of CAR-T cells upon antigen-specific stimulation. The predominant response is found to be a highly mixed T_H1/T_H2 function with T_{reg} activity emerges from a small fraction of this hybrid T_H1/T_H2 population. The cytokine response is minimally associated with differentiation states such as naïve, central memory, effector memory, and effector cells. All the results suggest that the activation of CAR-engineered T cells is a canonical process associated with a highly mixed multi-functional response, supporting the notion that polyfunctional CAR-T cells correlate with objective response of non-Hodgkin's lymphoma patients reported in a CD19 CAR-T clinical trial [19].

Results and discussions

Single-cell level measurement of transcriptional, cytokine, and cytotoxic function

We combined a set of single-cell techniques to interrogate CAR-T cells upon antigen specific stimulation (Figure 1A). This allowed us to quantitatively dissect the activation states related to subtypes, differentiation, and other factors such as intracellular signaling cascades, co-stimulators and immune checkpoints. CAR-T cells used in this study were manufactured through *ex vivo* transduction of autologous T cells with a CD19-BB-28-3z CAR construct, expansion for ~10 days using CD3/CD28 Dynabeads, and then purification by bead removal and enrichment for CAR expression. T cells were isolated from three healthy donors and for the purpose of this study the human B cell lymphoma Raji cell line was used as a target. Single-cell 3' mRNA transcriptome profiling was performed using a massively parallel cell barcoding method called scFTD-seq implemented in a bead-in-a-well microchip [14]. Single CAR-T cell cytolytic activity was measured by co-seeding CAR-T cells and target tumor cells in the microwell array to image the uptake of SYTOX Green nucleic acid dye [20] indicative of target cell lysis by CAR-T cells. Single-cell multiplex cytokine secretion assay was performed using a previously developed antibody barcode microchip assay [16,17,21], which was further modified in this study to co-measure cytotoxicity by seeding both CAR-T and tumor cells in the same single-cell protein secretion assay microchamber. Integrating all these single-cell analyses tools provides an unprecedented resolution to correlate the activation states such as anti-tumor cytotoxicity and cytokine response in single CAR-T cells to their phenotype, differentiation, signaling, and other characteristics.




Figure 1 Single-cell integrative analysis reveals varying degrees of CAR-T cell activation with direct correlation to cytotoxicity

A. Depiction of the workflow. Single-cell transcriptome, cytokine secretion, and live cell tracking of single-cell cytolytic activity analyses were used to characterize CAR-T cells. **B.** LDH assay confirms CAR-T cells used in this study are cytotoxic to the target CD19-expressing Raji cells (tumor cells). Percentage of cell death were measured by uptake of SYTOX Green, calculated as $60.02 \pm 2.41\%$ at 1:1, $90.1 \pm 1.36\%$ at 5:1, and $90.52 \pm 6.51\%$ at a 10:1 ratio of CAR-T:Raji cells. Data are shown as mean \pm SD. One-way ANOVA was performed for statistical analysis and *** indicates significant difference in cell death between cell ratio of 1:1 with that of 5:1 and 10:1 ($P < 0.01$). **C.** t-SNE analysis of single-cell transcriptomes from a duplicate activation experiment (CMB1 and CMB2) vs. unstimulated control (control), showing highly consistent and efficient activation of $>95\%$ CAR-T cells and four major clusters/states (C0–C3) with varying degrees of activation compared to control (C4). **D.** Normalized gene expression of the main cytokines in single cells from major clusters (C0–C4). **E.** Single-cell multiplex cytokine secretion assay revealing three ties of activity, each of which is a different combination of cytokines shown by hierarchical clustering using Manhattan distance. Each row represents a microwell with a successful target cell killing event and each column corresponds to a cytokine of interest. Color intensity correlates with log scale of normalized fluorescence intensity of cytokine detected. **F.** Cytokine secretion intensity is elevated in microchambers where a CAR-T cell killed target tumor cells. The fluorescence intensity of detected cytokines was normalized against background as described previously [17,21] and shown as arbitrary unit. **G.** PCA showing distinct grouping patterns of cytokines secreted between killing and no-killing cases. CAR, chimeric antigen receptor; t-SNE, t-distributed stochastic neighbor embedding; PCA, principal component analysis; IL, interleukin; TNF, tumor necrotic factor; IFN, interferon; GM-CSF, granulocyte-macrophage colony stimulating factor.

CAR activation leads to heterogeneous responses involving a range of cytokines, correlating directly to cytotoxicity

We first performed a population lactate dehydrogenase (LDH) release assay to detect the impact of CAR-T cells on the target Raji cells by co-culturing these cells for 6 h. As shown in Figure 1B, the CAR-T cells are highly cytotoxic (60% and 90% at the ratios of 1:1 and 5:1 for CAR-T:Raji cells, respectively). This observation is also confirmed by time-lapse imaging of SYTOX Green uptake (Figure S1A). The cytotoxicity was concurrently correlated with the secretion of a panel of cytokines, e.g., IFN γ , tumor necrotic factor α (TNF α), GM-CSF, interleukin 4 (IL4), IL5, IL8, and IL13, as detected with a protein microarray assay (Figure S1B).

We then conducted a single-cell massively parallel 3' mRNA sequencing using unstimulated (control) and stimulated CAR-T cells (replicates: CMB1 and CMB2). The stimulated cells were prepared by co-culturing with

CD19-expressing target cells for 6 h and then purified by magnetic cell sorting to remove target cells. The sequencing data were of high quality (Figures S2 and S3) and 3817 single CAR-T cell transcriptomes were obtained, which were visualized with t-distributed stochastic neighbor embedding (t-SNE) plots (upper panel, Figure 1C). We observed high consistency between replicates and highly efficient activation, with $<0.5\%$ of activated CAR-T cells (CMB1 in red and CMB2 in green) found in the control cluster (blue). Differential gene expression analysis (lower panel, Figure 1C and Figure S4) further identified four clusters C0–3 within the activated population that show varying degrees of cytokine responses (Figure 1D). Most cytokines measured are highly expressed in C0 and C1, moderately expressed in C2 and C3, as compared to the unstimulated control (C4). Single-cell 14-plex cytokine secretion assay confirms the heterogeneous activation with 3 clusters identified that secret most, nearly half, or very few cytokines, respectively (Figure 1E).

To correlate cytokine function directly to cytotoxicity, live cell imaging of SYTOX Green uptake was performed in the CAR-T:Raji cell pairs co-loaded in single-cell cytokine secretion microchambers over 12 h. The cytokine profiles are separated into no-killing and killing groups (Figure 1F and Figure S5). Rather than specific cytotoxic effector cytokines such as granzymes, the levels of a range of cytokines are elevated upon CAR activation and directly correlate to cytotoxic activity. Principal component analysis (PCA) revealed that upon CAR activation, the cytokines are grouped into two clusters, one dictated by $TNF\alpha$, $IFN\gamma$, granzyme B, GM-CSF, and IL8, and the other dictated by IL4, IL5, IL6, and IL17 (left panel, Figure 1G). In contrast, the cytokine profile from single CAR-T cells that did not kill tumor cells showed no distinguishable grouping (right panel, Figure 1G). A diverse landscape of antigen-specific response was observed in CD19-BB-3z CAR-T cells [13]. Their dominant polyfunctional cells also produce granzyme B, GM-CSF, IL8, $TNF\alpha$, IL13, and $IFN\gamma$, in concordance with our observation in this study using the third-generation CAR-T cells.

Both $CD4^+$ and $CD8^+$ CAR-T cells are highly cytotoxic and produce similar combination of cytokines at the proteomic and transcriptional level

In addition to the differentiated $CD4^+$ subsets discussed above, the cytotoxic $CD4^+$ T cells ($CD4^+$ CTL), which can secrete granzyme B and perforin, have been observed as a transient state during viral infections or in antitumor and chronic inflammatory responses [22]. Although $CD4^+$ CTL cells within the whole $CD4^+$ T cell population are supposedly very rare, 66% CAR-T cells in our study can secrete granzyme B, regardless $CD4^+$ or $CD8^+$ subtypes. To examine whether the varying degrees of CAR-T cell activation is a consequence of varying $CD4^+$ helper cell phenotype present in the CAR-T product, we conducted a SYTOX Green assay with target cells loaded in microfabricated wells ($100\ \mu\text{m} \times 100\ \mu\text{m}$) together with $CD4^+$ or $CD8^+$ CAR-T cells, respectively (Figure 2A and Movies S1 and S2). $CD4^+$ and $CD8^+$ CAR-T cells are equally efficient in killing target cells [23], both requiring similar time and distance to find and lyse target tumor cells. Our single-cell cytokine secretion (proteome) and mRNA expression (transcriptome) data showed that the frequency and levels of cytokine expression were nearly indistinguishable between $CD4^+$ and $CD8^+$ subsets, except a slight increase in the level of *GZMB* in $CD8^+$ cells and a slight upregulation in the expression of *IL4*, *IL5*, *IL13*, and *IL10* in $CD4^+$ cells (Figure 2B). Both subsets are highly polyfunctional, since more than 50% CAR-T cells co-secreted >5 cytokines, with a slightly higher polyfunctionality found in the $CD4^+$ subset (Figure 2C). PCA further confirms a similar pattern of cytokine grouping in both subsets (Figure 2D). This is consistent with previous findings [13] and supports the hypothesis that CAR-T cell activation is largely independent of class I or class II p-MHC signaling. CAR-T cells with defined CD4:CD8 composition have been investigated in treating B-ALL patients and demonstrated high potency, allowing for delineating factors correlated with expansion, persistence, and toxicity of the CAR-T cells [24]. Our results confirm the importance of $CD4^+$ cells in CAR-T product and the necessity to fully evaluate the role of these “helper” T cells in immunotherapy.

Mapping into subtypes reveals a predominantly mixed T_{H1}/T_{H2} response in conjunction with T_{reg} activity in the same CAR-T cells

To assess whether the observed heterogeneous activation depends on CAR-T cell polarization and subtypes, we examined the expression of master transcription factors (TFs) and signature cytokines. We found increased gene expression of type 1 and type 2 TFs, as well as the respective signature cytokine genes (Figure 2E). Expression of *FOXP3*, a master TF gene for T_{reg} cells, was detected in unstimulated cells and the frequency of *FOXP3*⁺ cells decreased upon CAR-T cell activation, which was associated with the elevated expression of *TGFB1* and *IL10*, the genes encoding regulatory cytokines TGF β and IL10. All these alterations are minimally dependent on CD4 or CD8 subtypes, despite a slightly higher type 2 activity in $CD4^+$ cells. Further mapping of all single $CD4^+$ cell transcriptomes into T_{H1} , T_{H2} , T_{H17} , T_{H9} , T_{reg} , and follicular helper T cell (T_{FH}) subtypes showed that T_{H1} and T_{H2} subtypes were dominant and the T_{reg} response was observed (Figure 2F). Although expression of *TBX21* (Tbet) was detected in 15.5% of cells, *IFNG* ($IFN\gamma$) was expressed in 85.6% of cells, suggesting that the IFN response is also elicited or amplified through T-bet-independent pathways, for example, STAT1 signaling. *GATA3* is expressed in 64.3% of cells, but the gene encoding predominant T_{H2} cytokine IL4 was expressed in 23.1% of these cells, with other T_{H2} cytokines (66% cells are *IL5*⁺ and 80.6% cells are *IL13*⁺) being more predominant. These data are indicative of a prevalent but slightly skewed T_{H2} response, consistent with the previous report that IL13 rather than IL4 is the dominant T_{H2} cytokine observed in CD19-BB-3z CAR-T cell activation [13]. Thus, for further analysis, *IL13* rather than *IL4* was chosen as the T_{H2} dominant cytokine gene.

To further answer if these are stringent polarization subtypes as in classic T cell biology, we quantified the frequency of dominant T_{H1} (*IFNG*), T_{H2} (*IL13*), and T_{reg} (*TGFB1*) responses in the same single cells. It turned out that the ~76% of $CD4^+$ CAR-T cells upon activation showed a mixed T_{H1} (*IFNG*) and T_{H2} (*IL13*) response, and 75% of T_{reg} (*TGFB1*) – like cells are triple positive for T_{H1} (*IFNG*) and T_{H2} (*IL13*) (Figure 2G). Therefore, CAR-T cell activation appears to differ substantially from classic T cells in that the predominant response is a highly mixed T_{H1}/T_{H2} phenotype, within which a fraction of cells further exhibits regulatory characteristics, presumably to counteract over-activation (Figure 2H). Hegazy et al has reported that interferons can direct T_{H2} cell reprogramming to generate a hybrid subset with combined T_{H2} and T_{H1} cell functions [25]. This could be a mechanism attributable in our CAR-T cells, given that *GATA3* is prevalently expressed and interferon response is the most profound, which together may confer T_{H1} function to *GATA3*⁺ CAR-T cells. Other mechanisms reported previously include stochastic cytokine expression leading to the formation of mixed helper T cell states [26]. Peine et al reported that stable T_{H1}/T_{H2} hybrid cells arise *in vivo* from naïve precursors to limit immunopathologic inflammation [27]. This may explain in part the observation that CAR-T cells in general show a balanced response in anti-tumor effect and inflammatory toxicity, despite the unusually wide range of cytokines co-produced per cell.




Figure 2 Mapping single-cell data to phenotypes reveals a highly mixed TH1/TH2 cell response

A. Single-cell cytolytic activity assay revealing that both CD4⁺ and CD8⁺ CAR-T cells are cytotoxic (on the left) and show insignificant difference in anti-tumor reaction (on the right). **B.** Comparing cytokine protein secretion (proteome) and gene expression (transcriptome) in single CAR-T cells between CD4⁺ and CD8⁺ subsets. **C.** Polyfunctionality, a term that defines the ability of a single cell to co-secrete multiple cytokines, is slightly higher in CD4⁺ than in CD8⁺ CAR-T cells. **D.** PCA revealing similar clustering of major cytokines secreted between CD4⁺ and CD8⁺ cells. **E.** Expression of type 1, type 2, and T_{reg} cell signature genes in single CAR-T cells upon activation. **F.** Quantification of CD4⁺ T cell subsets according to the expression of signature transcription factor and cytokine genes. **G.** Analysis of co-expression of T_H1, T_H2, and T_{reg} cytokine genes in single CAR-T cells and the alteration upon antigen-specific activation. NS, not significant; AU, arbitrary unit; T_H, helper T cell; T_{reg}, regulatory T cell; T_{FH}, follicular helper T cell. *t*-test was performed for statistical analysis.

GM-CSF is highly prevalent in activated CAR-T cells and co-produced with types 1 and 2 cytokines

GM-CSF is a potent pro-inflammatory cytokine involved in the recruitment, maturation, and activation of myeloid cells [28]. The helper T cells producing GM-CSF have been identi-

fied and recently reported to serve a nonredundant function in autoimmune pathogenesis, arguably representing a unique helper T cell subset [29]. The secretion of GM-CSF, a stimulator factor for monocytes and macrophages, may activate myeloid cells *in vivo* and amplifies systemic immunotoxicity [28]. Our data showed that > 80% of activated CD4⁺ cells express

CSF2, the gene encoding GM-CSF, which was confirmed independently by single-cell cytokine secretion (proteome) and single-cell mRNA sequencing (transcriptome) (Figure S6). We observed that 89% of *TBX21*⁺ cells and 83.5% of *GATA3*⁺ cells express *CSF2*. Previously, it was found that *STAT5* programs a distinct subset of GM-CSF-producing Th cells in neuro-inflammation and autoimmunity [30]. In this study, 65.2% of *CSF2*-expressing CD4⁺ CAR-T cells were negative or low for *STAT5* expression. Instead, we observed the expression of a wide range of *STAT* genes, but *STAT1* is predominant, which may contribute to the profound T_H1 interferon response despite a modest level of *TBX21* (T-bet) expression. Our gene set enrichment analysis (GSEA) confirmed the relevance of *STAT5* signaling and also revealed the importance of *IL6/STAT3* (Figure S7), which has been observed as a determinant of CAR-T memory phenotype and therapeutic persistence in patients [31]. The JAK/STAT signaling relies on phosphorylation of *STATs* and their nuclear translocation. The mechanism leading to a prevalent GM-CSF-positive phenotype in activated CAR-T cells is yet to be further investigated.

Cytokine production in CAR-T cells upon antigen-specific activation is minimally dependent on differentiation status

To examine if the activation state of CAR-T cells is dependent on the differentiation status, we stratified the transcriptomes of single cells (both control and activated) into four subsets: naïve (T_N), central memory (T_{CM}), effector memory (T_{EM}), and effector (T_{EFF}) T cells, based on the expression of marker genes *CD45RA* and *CCR7* [32,33]. T cell subsets have been shown to persist following transduction with the CAR construct and antigen stimulation [34,35]. The T_N-like subset herein may also contain T stem-cell memory (T_{SCM}) phenotype. We found that both CD4⁺ and CD8⁺ populations mainly comprised naïve-like and effector-like cells based on the expression of marker genes, but central memory and effector memory phenotypes were also observed (Figure 3A). CAR-T cell activation led to the increased frequencies of T_{CM}-like and T_{EM}-like cells and as a result a reduced frequency of T_N-like cells. However, when we analyzed the correlations between the cell differentiation status and the expression of a range of stimulatory and cytotoxic cytokine genes that are




Figure 3 Correlating differentiation status of CAR-T cells to cytokine functions reveals minimal dependence

A. Stratification of unstimulated and stimulated CAR-T cells into different differentiation status using a pair of gene markers *CD45RA* and *CCR7*. **B.** Correlating cytokine gene expression in CD4⁺ cells to differentiation status. **C.** Expression of T cell growth factor receptor genes *IL2RA* and *IL15RA* in different subsets of CAR-T cells upon activation. **D.** A model describing the activation of CAR-T cells to produce effector cytokines, largely independent of differentiation status. T_N, naïve T cell; T_{CM}, central memory T cell; T_{EM}, effector memory T cell; T_{EFF}, effector T cell.

involved in T_{H1} , T_{H2} , and T_{reg} phenotypes in $CD4^+$ cells, we found no or minimal dependence on differentiation status (Figure 3B). A closer look revealed a slight increase in *TNF* expression and a modest decrease in the expression of T_{H2} cytokine genes (e.g., *IL4* and *IL13*) in the T_{CM} -like subset (red bars in Figure 3B). CAR-T product containing central memory cells has been reported to be correlated with *in vivo* expansion, persistence, and potency [34]. Thus, the role of T_{CM} -like subset in CAR-T cell activation requires further investigation.

In addition, we examined the expression pattern of *IL2RA* and *IL15RA*, the genes encoding T cell growth factor receptors *IL2RA* (CD25) and *IL15RA*, in the four aforementioned subsets of $CD4^+$ and $CD8^+$ CAR-T cells. There is no statistically significant difference found either (Figure 3C). Interestingly, *IL2RA* is also a marker gene for T_{reg} cells. $CD4^+CD25^+$ T cells are considered as immunosuppressive and often used as a surrogate for $Foxp3^+$ T_{reg} cells [36]. In this study, nearly 100% of CAR-T cells upon activation were *IL2RA*-positive (Figure 3C) but apparently did not exert the suppressor function, highlighting the importance to characterize the function of CAR-T cells following activation in addition to surface

marker phenotyping. A model to describe CAR-T activation as a function of differentiation states is shown in Figure 3D. It is worth noting that the differentiation status of CAR-T cells manufactured from healthy donors and patients with B cell malignancies could differ substantially and the patient samples can contain significantly higher percentage of central and effector memory cell subsets [24]. However, the fundamental mechanism revealed in this study regarding CAR-T cell activation as a function of differentiation status (e.g., T_N , T_{CM} , T_{EM} , and T_{EFF}) should still hold true.

CAR-T cell activation leads to elevated expression of *CTLA4* that correlates with upregulation of *IL10* in $CD4^+$ and *TGFB1* in $CD8^+$ subsets

To investigate the possible relationship between CAR-T cell activation and the changes in the expression of co-stimulators or immune checkpoints, we examined their expression in single-cell transcriptomes. We observed that *CTLA4* is the most upregulated genes among all immune checkpoint genes upon CAR-T cell activation (Figure 4A). *PDCD1*, the gene encoding checkpoint protein programmed cell death




Figure 4 Effect of activation state on the gene expression of co-inhibitors and co-stimulators
A. Gene expression profiles of common co-stimulators (*ICOS* and *OX40*) and co-inhibitors (*BTLA*, *CTLA4*, and *PDCD1*) in $CD4^+$ and $CD8^+$ subpopulations of activated and control CAR-T cells. In the $CD4^+$ subset population, *CTLA4* expression doubles from the control (26%) to the activated state (58.8%) while there is a slight decrease in the co-stimulatory *ICOS* expression from 77.2% in the control state to 57.6% in the activated state. **B.** Percentage of cells expressing three different combinations of *CTLA4* and *ICOS* expression are plotted and compared. **C.** Gene expression of T_{H1} (*IFNG* and *TNF*), T_{H2} (*IL13*), and T_{reg} (*IL10*) markers in the three cell populations shown in B.

protein 1 (PD-1), demonstrates a similar trend. However, *PDCDI* was lowly expressed and its expression was only detected in 9.8% CD4⁺ and 3.7% CD8⁺ subsets. Given PD-1 is also the primary marker of T cell exhaustion [37], our data suggest an infrequent incidence of acute stimulation-induced exhaustion following CAR-T cell action.

Concurrently, there is a decreased frequency of *ICOS* and *Ox40* expression but slightly increased expression levels of these genes in a fraction of cells (Figure 4A). Correlation analysis revealed that unstimulated cells are predominantly *ICOS*⁺ *CTLA4*⁻, whereas all three expression status combinations of these two genes were readily observed in the activated cells, and the *ICOS*⁺ *CTLA4*⁺ subset was dominant in CD4⁺ CAR-T cells (Figure 4B). All three subsets of cells were capable of producing effector cytokines after activation (Figure 4C). Finally, the question is whether the significant upregulation of *CTLA4* correlates or may contribute to the observed cytokine response heterogeneity. Comparing *CTLA4*-high (top 10%) cells to *CTLA4*-low (bottom 10%) cells for a range of cytokines (Figure S8), we observed significant increases in *IL10* and *TGFBI* expression in CD4⁺ subset, as well as *TGFBI* expression in CD8⁺ subset, whereas expression of other cytokine genes was minimally or insignificantly correlated with the *CTLA4* expression level. These findings suggest a possible mechanism for CAR-T cells to control immune homeostasis without developing distinct regulatory subtypes, which has important implications in combining checkpoint blockage and CAR-T targeted immunotherapies [38–40].

Conclusions

In this study, we employ high-throughput single-cell 3' mRNA transcriptome sequencing, multiplexed single-cell cytokine secretion assay, together with live cell imaging of cytotolytic activity, to interrogate third-generation anti-CD19 4-1BB/CD28/CD3ζ (CD19-BB-28-3z) CAR-T cells at the systems level [41] upon antigen-specific activation. CD4⁺ and CD8⁺ CAR-T cells are found to be equally effective in direct killing of target tumor cells and the cytotoxic activity is associated with the elevated co-production of a wide range of cytokines. Both T_{H1} and T_{H2} responses are prevalent, as confirmed by the expression of master TF genes *TBX21*(T-bet) and *GATA3*, as well as signature cytokine genes (proteins) including *IFNG* (IFNγ), *TNF* (TNFα), *IL5* (IL5), and *IL13* (IL13). T_{reg} cell activity, although detected in a small fraction of CAR-T cells, is associated with elevated *TGFBI* and *IL10* expression. Unexpectedly, all these responses are often observed in the same CAR-T cells rather than distinct subsets, supporting the notion that polyfunctional CAR-T cells correlate with objective response of patients in clinical trials [14]. GM-CSF is produced from the majority of CAR-T cells regardless of the polarization state, further contrasting CAR-T cells to conventional T cells. We find that the cytokine response is minimally dependent on differentiation status although all major subsets such as naïve-like, central memory-like, effector memory-like, and effector-like cells are all detected.

Antigen-specific activation increases the level and frequency of cells expressing immune checkpoints such as *CTLA4* and *PDCDI*, and slightly reduces the frequency of co-stimulator expression, which correlates with elevated expression of immunosuppressive cytokine genes like *IL10* and *TGFBI*. In

summary, the activation states of these CAR-T cells are highly mixed with T_{H1}, T_{H2}, T_{reg}, and GM-CSF-expressing T cell responses in the same single cells and largely independent of differentiation status.

This study provides the first comprehensive portrait of CAR-T cell activation states at the single-cell level. Although CAR-T cell activation states may differ between patients, our work does reveal some common mechanisms regarding how different subtypes of CAR-T cells respond to antigen-specific challenge. It provides valuable information about the third-generation CD19-BB-28-3z CAR-T cells, which are being used in clinical trials to further improve therapeutic efficacy for non-responding patients. Our work sheds new insights on the biology of CAR-T cell activation and a rational path to develop single-cell approaches for CAR-T infusion product quality assurance and to monitor the changes of CAR-T cells in patients post infusion in clinical trials.

Methods

Cell culture and labeling

Human anti-CD19scFv-CD28-4-1BB-CD3ζ (Catalog No. PM-CAR-1002, Promab, Richmond, CA) T cells were cultured in complete X-Vivo 10 (Catalog No. 04-743Q, Lonza, Morris-town, NJ) medium supplemented with IL2 (10 ng/ml, Catalog No. 589102, BioLegend, Dedham, MA) at a concentration of 5 × 10⁵ cells/ml. To identify the CD4⁺ and CD8⁺ subsets, 1 × 10⁵ CAR-T cells were pelleted and resuspended in 100 μl of PBS containing anti-human CD4 FITC (Catalog No. 130-113-213, Miltenyi Biotec, Somerville, MA) and anti-human CD8 Alexa Fluor 647 (Catalog No. 557708, BD Biosciences, Billerica, MA). The labeling reaction was incubated for 15 min at room temperature in the dark. The cells were then rinsed twice in PBS and once in complete RPMI medium (Catalog No. 11875085, Thermo Fisher, Waltham, MA) with 10% FBS (v/v; Catalog No. SER-500, Zenbio, Research Triangle, NC). Raji cells (Catalog No. CCL-86, ATCC, Manassas, VA) were labeled with Vybrant DiD (Catalog No. V22887, Thermo Fisher) following the manufacturer's instructions. Briefly, the Raji cells were resuspended at a density of 1 × 10⁶ cells/ml in serum-free RPMI containing 5 μl/ml of Vybrant DiD solution and incubated for 20 min at 37 °C. The labeled cells were then washed three times in complete RPMI medium and kept at 4 °C before use.

CAR-T cell stimulation with target tumor cells

CAR-T cells and Raji cells (5 × 10⁴ cells/ml concentration) were incubated for 6 h in a round bottom well plate. Afterward, Raji cells were separated from co-culture by positive selection using a protocol of B cell selection with MagCelect (Catalog No. MAG997, R&D Systems, Minneapolis, MN). Briefly, CAR-T:Raji cell co-culture was centrifuged and the cell pellet was resuspended in serum-free RPMI medium and labeled with anti-CD19 biotinylated antibodies (Catalog No. 302204, BioLegend). Following manufacturer's protocol, MagCelect Streptavidin Ferrofluid was added to the solution and the mixture was incubated for the recommended amount of time according to the product manual. The Streptavidin Ferrofluid beads bound to the anti-CD19 biotinylated Raji

cells were collected on the side of the test tube by applying a magnet and then the CAR-T cells were pipetted out of the reaction. This procedure is repeated twice to make sure that most Raji cells were separated. The isolated CAR-T cells were then added to the microwell array device we fabricated for mRNA capture and transcriptome sequencing. Unstimulated CAR-T cells (5×10^4 cells/ml) were incubated for 6 h alone before subjected to single-cell RNA sequencing (scRNA-seq).

Bulk LDH cytotoxicity assessment

Cytotoxicity was assessed using the Pierce LDH Cytotoxicity Assay kit (Catalog No. 88953, Thermo Fisher). The effector cells and target cells were mixed at three ratios, *i.e.*, 1:1, 5:1, and 10:1. Target and effector cells were incubated for 6 h in complete RPMI medium at a final concentration of 7×10^5 cells/ml. LDH release was measured in the supernatant according to manufacturer's instructions. Maximum LDH release was obtained by incubating target cells in the provided $10\times$ lysis buffer. Target cell cytotoxicity was calculated using the following formula: % of cytotoxicity = $100 \times [(CAR-T: target cells - CAR-T cells alone - target cells alone) / (maximum target cell lysis - target cells alone without lysis buffer)]$.

Population SYTOX Green cytotoxicity assay

Effector CAR-T cells and the labeled target Raji cells were co-cultured in a 96 well U-bottom plate at three ratios, *i.e.*, 1:1, 5:1, and 10:1. Raji cells at the concentration of 1×10^4 cells/ml were mixed with CAR-T cells at the concentrations of 1×10^4 , 5×10^4 , and 1×10^5 cells/ml to obtain the ratios mentioned above. To distinguish cell death, SYTOX Green (Catalog No. S34860, Thermo Fisher) was added to each well according to manufacturer's instructions. Images were taken at 0, 4, 6, and 10 h of co-culture using the Nikon Eclipse Ti microscope.

Single CAR-T cell cytotoxicity assay in a microwell array

$100 \mu\text{m} \times 100 \mu\text{m}$ nanowell array was prepared by curing poly (dimethylsiloxane) (PDMS; Dow Corning Sylgard 184, Catalog No. 184 SIL ELAST KIT 3.9 KG, Ellsworth Adhesives, Germantown, WI) on a silicon wafer master with the etched array design. The nanowell array was cut to fit within the well of a 24-well plate and it was surface-treated with oxygen plasma prior to cell loading to decrease PDMS hydrophobicity [42]. Labeled Raji (target) and CAR-T cells (effector), as described above, were seeded at a density of 1×10^5 cells/ml. Stochastic distribution of the cells within the array allowed for a wide range of effector:target cell ratios. Images were acquired on a Nikon Eclipse Ti microscope fitted with an incubation chamber (37°C and $5\% \text{CO}_2$) using a $10\times/0.3$ objective. Automated multi-loci images were taken at 15 min intervals for a total duration of 10 h. Images were processed using the built-in Nikon software.

Fabrication of antibody barcode array slides and single-cell microchamber array chip

A panel of 14 anti-human antibodies is listed in Table S1 (IL2, IL4, IL5, IL6, IL8, IL10, IL12p70, IL13, IL17a, granzyme B,

TNF α , TNF β , IFN γ , and GM-CSF). FITC-BSA serving as the alignment control (Catalog No. A23015, Thermo Fisher), was patterned onto a poly-L-lysine glass slide using an air-pressure driven flow through a PDMS mold with 20 microfluidic channels. The PDMS mold was fabricated in-house as previously described [16,17]. The subnanoliter microchamber array for cell capture contains 14 columns of 220 wells and was fabricated into a PDMS slab. Prior to cell loading, the microchamber PDMS slab was treated with oxygen plasma and then topped with RPMI medium.

Single-cell cytokine secretion profiling

Single-cell antibody barcode chips (SCBCs) for single-cell cytokine secretion profiling were developed in our laboratory as described previously [16,17,21,43]. Following labeling, CAR-T and Raji cells were incubated at the ratio of 1:1 for 15 min in RPMI medium that was supplemented with SYTOX Green at a final concentration of $0.2 \mu\text{M}$. The suspension was then gently pipetted onto the microchamber array. The SCBC device was assembled by overlaying the 14-plex antibody barcode glass slide and secured using our clamping system. The cell-loaded device was imaged (Nikon Eclipse Ti microscope) twice at 0 h and 14 h, respectively after incubation (37°C and $5\% \text{CO}_2$). Number of CD4 $^+$ CAR-T, CD8 $^+$ CAR-T, and Raji cells, as well as cell-to-cell contact and Raji cell death were recorded for each microchamber from the phase-contrast and fluorescent images. After the 14-h incubation, the antibody barcode chip was developed using an ELISA sandwich immunoassay as previously described [16]. The developed slides were scanned using the GenePix 4200A microarray scanner (Molecular Devices, Downingtown, PA).

Single-cell cytokine profiling data analysis

The fluorescent signals were processed using the GenePix software and a custom Excel macro was used to determine the average fluorescent signal for each secreted cytokine. The threshold gate (background) used for cytokine intensity normalization was calculated according to the formula: average of raw mean fluorescence intensity of a given cytokine for the 0-cell wells + $2 \times$ (standard deviation of raw mean fluorescence intensity of a given cytokine for the 0-cell wells) [44]. Secretors were defined as cells in the microchambers where the corresponding fluorescence cytokine signal intensity was higher than the threshold. We performed log transformation on the normalized cytokine intensity values (raw fluorescence intensity of a secretor for each cytokine - threshold gate for each cytokine) and applied single-cell analysis visualization tools to represent such large-scale high-dimensional data with PCA and viSNE [45]. All single-cell secretomic analysis was analyzed using Excel, R, and MATLAB.

Population-level cytokine secretion measurement of CAR-T:Raji cell pairs

CAR-T cells were co-incubated with target cells, both at the density of 1×10^5 cells/ml, in triplicates in a u-bottom 96-well plate with the effector:target cell ratio of 1:1. CAR-T cells alone and Raji cells alone were included in the same plate at the same concentration as the control. After a 10-h incubation,

the cell suspension was pelleted at 200 g and the supernatant was removed and the population cytokine assay was performed as previously described [16,17].

High-throughput scRNA-seq using a microwell array chip and data analysis

The massively parallel 3' mRNA sequencing of single cells (called scFTD-seq) [14,46] was based upon a closed microwell array system for co-isolation of single cells and DNA barcode beads. The chemistry was modified from the previous publications [47]. Briefly, the cell suspension prepared as described above was pipetted onto the inlet of the flow cell of our microchip, in which the entire bottom surface of the flow cell was covered by around 15,000 microwells (40 μ m in diameter) to allow for trapping of single cells. The cells were withdrawn into the device using a negative pressure applied to the outlet. Once the microwell array was filled with the cell solution, the fluid flow was stopped and cells were allowed to settle by gravity into the wells. Excessive cells were washed out by PBS and mRNA capture beads were then loaded similarly to the cells. Excessive beads were also washed out by PBS and then lysis buffer [14,46] was introduced into the device. Fluorinated oil (Fluorinert FC-40, Catalog No. 86508-42-1, Sigma–Aldrich, St. Louis, MO) was withdrawn into the device to seal the wells. Following lysis, the microfluidic device was incubated for 1 h inside a humidity chamber to allow mRNA capture onto the beads. Reverse transcription, library construction, and sequencing were performed as previously discussed [14,46]. Sequencing libraries were constructed using Nextera XT according to the manufacturer's protocol (Illumina). The finished libraries were sequenced on the HiSeq 2500 sequences (Illumina). The transcripts were then aligned to the reference human transcriptome hg19 using STAR v2.5.2b. The resulting gene expression matrices were analyzed using the Seurat package in R studio, custom built algorithms in R, MATLAB, as well as Excel and GraphPad Prism were used for plotting.

Statistical analysis

One-way ANOVA and *t*-tests were used to determine *P* values and difference with *P* < 0.05 is assumed to be statistically significant. Data were analyzed using GraphPad Prism V.7.0 and presented as mean \pm STD.

Data availability

The single-cell RNA-seq data are available in the Gene Expression Omnibus (GEO) as GEO: GSE129007.

Authors' contributions

RF conceived and designed the project; IX, BD, and GHL conducted experiments; DK and YX performed validation and support studies; IX, BD, GHL, and RF performed data analysis. IX and RF wrote manuscript with inputs from all other authors. All authors read and approved the final manuscript.

Competing interests

RF serves on the Scientific Advisory Boards of IsoPlexis, BioTechne, and Singleron Biotechnologies.

Acknowledgments

This research was supported by the Packard Fellowship for Science and Engineering, the CAREER award from the National Science Foundation (NSF), United States (Grant No. CBET-1351443), the grants from National Institutes of Health (NIH), United States (Grant No. U54 CA193461 and Sub-Project 7297 of Grant No. U54 CA209992), the Co-Pilot Grant from Yale Cancer Center, United States, to RF. Sequencing was performed at the Yale Center for Genome Analysis (YCGA) facility, United States. We used the Core facilities at the Yale Cooperative Center of Excellence in Hematology, supported by National Institutes of Health, United States (NIH U54DK106857). The molds for microfluidic devices were fabricated in the Yale School of Engineering and Applied Science cleanroom. We graciously thank Michael Power, Chris Tillinghast, and James Agresta for their help with fabrication process.

Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.gpb.2019.03.002>.

References

- [1] Sadelain M. CAT therapy: the CD19 paradigm. *J Clin Invest* 2015;125:3392–400.
- [2] Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *New Engl J Med* 2011;365:725–33.
- [3] Park JH, Riviere I, Gonen M, Wang XY, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *New Engl J Med* 2018;378:449–59.
- [4] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *New Engl J Med* 2017;377:2531–44.
- [5] June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? *Nat Med* 2017;23:540–7.
- [6] Davila ML, Riviere I, Wang XY, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med* 2014;6:224ra25.
- [7] Sadelain M, RiviSre I, Riddell S. Therapeutic T cell engineering. *Nature* 2017;545:423–31.
- [8] Sadelain M. CD19 CAR T cells. *Cell* 2017;171:1471.
- [9] Kalyuzhny AE. Chemistry and biology of the ELISPOT assay. *Methods Mol Biol* 2005;302:15–31.
- [10] Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. *J Immunol* 2008;180:4901–9.
- [11] Jena B, Moyes JS, Huls H, Cooper LJ. Driving CAR-based T-cell therapy to success. *Curr Hematol Malig Rep* 2014;9:50–6.
- [12] Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, Bethke U, et al. Towards a commercial process for the manufac-

- ture of genetically modified T cells for therapy. *Cancer Gene Ther* 2015;22:72–8.
- [13] Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, et al. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. *J Immunother Cancer* 2017;5:85.
- [14] Dura B, Choi JY, Zhang K, Damsky W, Thakral D, Bosenberg M, et al. scFTD-seq: freeze-thaw lysis based, portable approach toward highly distributed single-cell 3' mRNA profiling. *Nucleic Acids Res* 2019;47:e16.
- [15] Deng Y, Finck A, Fan R. Single-cell omics analyses enabled by microchip technologies. *Annu Rev Biomed Eng* 2019;21:365–93.
- [16] Lu Y, Chen JJ, Mu LY, Xue Q, Wu Y, Wu PH, et al. High-throughput secretomic analysis of single cells to assess functional cellular heterogeneity. *Anal Chem* 2013;85:2548–56.
- [17] Lu Y, Xue Q, Eisele MR, Sulistijo ES, Brower K, Han L, et al. Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands. *Proc Natl Acad Sci U S A* 2015;112:E607–15.
- [18] Yu PJ, Lin W. Single-cell transcriptome study as big data. *Genomics Proteomics Bioinformatics* 2016;14:21–30.
- [19] Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, et al. Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin's lymphoma. *Cancer Res* 2017;77:nr2990.
- [20] Jones LJ, Singer VL. Fluorescence microplate-based assay for tumor necrosis factor activity using SYTOX Green stain. *Anal Biochem* 2001;293:8–15.
- [21] Xue Q, Lu Y, Eisele MR, Sulistijo ES, Khan N, Fan R, et al. Analysis of single-cell cytokine secretion reveals a role for paracrine signaling in coordinating macrophage responses to TLR4 stimulation. *Sci Signal* 2015;8:ra59.
- [22] Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4⁺ T cells, their differentiation and function. *Front Immunol* 2017;8:194.
- [23] Varadarajan N, Liadi I, Romain G, Singh H, Cooper LNJ. Quantitative single-cell functional characterization of CD19-specific CAR⁺ T cells for immunotherapy. *Cancer Res* 2013;73:nr4745.
- [24] Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4⁺:CD8⁺ composition in adult B cell ALL patients. *J Clin Invest* 2016;126:2123–38.
- [25] Hegazy AN, Peine M, Helmstetter C, Panse I, Frohlich A, Bergthaler A, et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3⁺T-bet⁺ cell subset with combined Th2 and Th1 cell functions. *Immunity* 2010;32:116–28.
- [26] Fang MQ, Xie HM, Dougan SK, Ploegh H, van Oudenaarden A. Stochastic cytokine expression induces mixed T helper cell states. *PLoS Biol* 2013;11:e1001618.
- [27] Peine M, Rausch S, Helmstetter C, Frohlich A, Hegazy AN, Kuhl AA, et al. Stable T-bet⁺GATA-3⁺ Th1/Th2 hybrid cells arise *in vivo*, can develop directly from naive precursors, and limit immunopathologic inflammation. *PLoS Biol* 2013;11 e1001633.
- [28] Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. *Immunity* 2016;45:963–73.
- [29] Herndler-Brandstetter D, Flavell RA. Producing GM-CSF: a unique T helper subset? *Cell Res* 2014;24:1379–80.
- [30] Sheng W, Yang F, Zhou Y, Yang H, Low PY, Kemeny DM. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. *Cell Res* 2014;24:1387–402.
- [31] Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med* 2018;24:563–71.
- [32] Riddell SR, Sommermeyer D, Berger C, Liu L, Balakrishnan A, Salter A, et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. *Cancer J* 2014;20:141–4.
- [33] Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. *Cancers (Basel)* 2016;8:E36.
- [34] Wang XL, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase I studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. *Blood* 2016;127:2980–90.
- [35] Schmueck-Henneresse M, Omer B, Shum T, Tashiro H, Mamonkin M, Lapteva N, et al. Comprehensive approach for identifying the T cell subset origin of CD3 and CD28 antibody-activated chimeric antigen receptor-modified T cells. *J Immunol* 2017;199:348–62.
- [36] Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4⁺CD25⁺ immunoregulatory T cells: new therapeutics for graft-versus-host disease. *J Exp Med* 2002;196:401–6.
- [37] Kato T, Nishida T, Murase M, Murata M, Naoe T. Exhaustion of CMV specific T cells with enhanced PD-1 expression in persistent cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 2010;116:3912.
- [38] Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *J Clin Invest* 2016;126:3130–44.
- [39] Fedorov VD, Themeli M, Sadelain M. PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. *Sci Transl Med* 2013;5:215ra172.
- [40] Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood* 2017;129:1039–41.
- [41] Hood L, Tian Q. Systems approaches to biology and disease enable translational systems medicine. *Genomics Proteomics Bioinformatics* 2012;10:181–5.
- [42] Eddington DT, Puccinelli JP, Beebe DJ. Thermal aging and reduced hydrophobic recovery of polydimethylsiloxane. *Sens Actuators B Chem* 2006;114:170–2.
- [43] Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. *Blood* 2018;132:804–14.
- [44] Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. *Cancer Discov* 2015;5:316–31.
- [45] Amir ED, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* 2013;31:545–52.
- [46] Wang N, Zheng J, Chen Z, Liu Y, Dura B, Kwak M, et al. Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation. *Nat Commun* 2019;10:95.
- [47] Macosko EZ, Basu A, Satija R, Nemes J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. *Cell* 2015;161:1202–14.